Can open-source R&D reinvigorate drug research?

scientific article

Can open-source R&D reinvigorate drug research? is …
instance of (P31):
scholarly articleQ13442814

External links are
P6179Dimensions Publication ID1015162877
P356DOI10.1038/NRD2131
P698PubMed publication ID16915233
P5875ResearchGate publication ID6873077

P50authorBernard MunosQ92482166
P2860cites workOpen Source BiotechnologyQ114953146
Finding cures for tropical diseases: is open source an answer?Q21144737
Optimizing the use of open-source software applications in drug discoveryQ33236305
Virtual drug discovery and development for neglected diseases through public-private partnershipsQ35605447
The case for open-source software in drug discoveryQ36039834
Open-source software: not quite endsvilleQ36039842
An enhanced version of SMMP—open-source software package for simulation of proteinsQ58429761
P433issue9
P921main subjectopen-source softwareQ1130645
drug discoveryQ1418791
P304page(s)723-729
P577publication date2006-08-18
P13046publication type of scholarly workreview articleQ7318358
P1433published inNature Reviews Drug DiscoveryQ45998
P1476titleCan open-source R&D reinvigorate drug research?
P478volume5

Reverse relations

cites work (P2860)
Q38430706A call for sharing: adapting pharmaceutical research to new realities.
Q28475314A kernel for open source drug discovery in tropical diseases
Q39327679A kernel for the Tropical Disease Initiative
Q26783545A systematic review and critical assessment of incentive strategies for discovery and development of novel antibiotics
Q97644209Accelerating Therapeutics for Opportunities in Medicine: A Paradigm Shift in Drug Discovery
Q42376673Antimicrobial agents - optimising the ecological balance
Q33280919Building a pharmacological lexicon: small molecule discovery in academia
Q38140168Catecholamine receptors: prototypes for GPCR-based drug discovery.
Q29617272Chemical genetics of Plasmodium falciparum
Q56509596Clinical Trial Data as Public Goods: Fair Trade and the Virtual Knowledge Bank as a Solution to the Free Rider Problem - A Framework for the Promotion of Innovation by Facilitation of Clinical Trial Data Sharing among Biopharmaceutical Companies in t
Q113295220Collaborative writing applications in support of knowledge translation and management during pandemics: A scoping review
Q35505170Common characteristics of open source software development and applicability for drug discovery: a systematic review
Q88775542Considerations for a business model for the effective integration of novel biomarkers into drug development
Q64120525Crowdsourcing in medical research: concepts and applications
Q114954115Cumulative Innovation, Open Source and Distance to Frontier
Q114980949Cumulative innovation, open source, and distance to frontier
Q36952364Designing drugs on the internet? Free web tools and services supporting medicinal chemistry
Q62563630Developing and Implementing a Combined Chemistry and Informatics Curriculum for Undergraduate and Graduate Students in the Czech Republic
Q37118507Distributed Drug Discovery, Part 1: linking academia and combinatorial chemistry to find drug leads for developing world diseases
Q37769787Do technical and commercial biases contribute to the pharmaceutical industry's productivity problems? An analysis of how reordering priorities can improve productivity
Q38428344Drug discovery market exclusivity after KSR:The challenge to pharmaceutical scientists and the US congress
Q55051971Drug discovery. Repurposing with a difference.
Q30490232From Gutenberg to Open Science: An Unfulfilled Odyssey
Q108588832Functional and Material Properties in Nanocatalyst Design: A Data Handling and Sharing Problem
Q114928511Geographies of Open Source Biotechnology Innovation
Q88601256Highly Priced Gene Therapies: A Wake-Up Call for Early Price Regulation
Q36954603Incentives for biodefense countermeasure development
Q114733139Inclusive innovation: Enhancing global participation in and benefit sharing linked to the utilization of marine genetic resources from areas beyond national jurisdiction
Q29237434Is Open Science the Future of Drug Development?
Q56463368Is open innovation the way forward for big pharma?
Q43447062Lessons from 60 years of pharmaceutical innovation
Q39076702Mission possible
Q43186796More medicines for neglected and emerging infectious diseases
Q45174630Multifaceted roles of ultra-rare and rare disease patients/parents in drug discovery
Q48146898Navigating the Patent Landscapes for Nanotechnology: English Gardens or Tangled Grounds?
Q57201013New therapeutic targets in immune disorders: ItpkB, Orai1 and UNC93B
Q37397444Novel web-based tools combining chemistry informatics, biology and social networks for drug discovery
Q30488815Open Access Could Transform Drug Discovery: A Case Study of JQ1.
Q21092921Open Data, Open Source and Open Standards in chemistry: The Blue Obelisk five years on
Q28647980Open Source Bayesian Models. 1. Application to ADME/Tox and Drug Discovery Datasets
Q26883657Open Source Drug Discovery: Highly Potent Antimalarial Compounds Derived from the Tres Cantos Arylpyrroles
Q21202760Open access and open source in chemistry
Q115037238Open data partnerships between firms and universities: The role of boundary organizations
Q55004173Open innovation and external sources of innovation. An opportunity to fuel the R&D pipeline and enhance decision making?
Q84585106Open innovation: share or die...
Q21004179Open science is a research accelerator
Q85167542Opening Up to Precompetitive Collaboration
Q51721104Opinion: Open Innovation: An Answer for Neglected Diseases
Q37692185Overcoming the obstacles in the pharma/biotech industry: 2009 update
Q56511193Pioneering Use of the Cloud for Development of Collaborative Drug Discovery (CDD) Database
Q57699007Policies and Practices to Enhance Multi-sectorial Collaborations and Commercialization of Regenerative Medicine
Q29999056Portfolio Decisions in Early Development
Q84393405Rethinking leadership in drug discovery projects
Q46412472Returning to the Patent Landscapes for Nanotechnology: Assessing the Garden that It Has Grown Into
Q38695331Screening the Medicines for Malaria Venture Pathogen Box across Multiple Pathogens Reclassifies Starting Points for Open-Source Drug Discovery.
Q38055974Social networks, web-based tools and diseases: implications for biomedical research
Q56399917Standards for Collaborative Computational Technologies for Biomedical Research
Q28534065Target prediction for an open access set of compounds active against Mycobacterium tuberculosis
Q86561584The Collaborative Drug Discovery (CDD) database
Q61663288The Role of Genomics and Genetics in Drug Discovery and Development
Q37135923The role of users in innovation in the pharmaceutical industry
Q36727206Treating desires not diseases: a pill for every ill and an ill for every pill?

Search more.